(HealthDay)—For patients undergoing hemodialysis, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-1273 vaccine elicits a stronger humoral response than the BNT162b2 vaccine, according to a study published ...
Feb 16, 2022
0
4
As the effort to combat the SARS-CoV-2 virus began, among the most pressing questions were how to gauge its infectivity and get a better picture of those dynamics from the inside out. Answering them initially would bring ...
Mar 15, 2022
0
87
New computational simulations of the behavior of SARS-CoV-1 and SARS-CoV-2 spike proteins prior to fusion with human cell receptors show that SARS-CoV-2, the virus that causes COVID-19, is more stable and slower-changing ...
Mar 30, 2022
0
42
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 infection has led to worsened outcomes for patients with cancer. SARS-CoV-2 spike protein mediates host cell infection and cell-cell fusion that causes ...
May 7, 2024
1
7
As Americans cross their fingers, hoping the pandemic stays behind them, scientists across the country remain focused on the novel coronavirus, intent on combating its next move.
Mar 28, 2022
0
68
Structural biologists at The Hong Kong University of Science and Technology (HKUST) together with researchers at the AIDS Institute, The University of Hong Kong (HKU), Department of Microbiology, School of Clinical Medicine, ...
Jul 11, 2022
0
67
A new study led by scientists at La Jolla Institute for Immunology (LJI) shows how ideal antibodies against SARS-CoV-2 hit their marks.
Jan 17, 2023
0
64
A Johns Hopkins Medicine research team has shown that people living with the human immunodeficiency virus (HIV) are likely to be protected against SARS-CoV-2, the virus that causes COVID-19, if they are fully vaccinated.
Aug 11, 2021
0
202
COVID vaccines have been available to adults in the United States for more than a year, but there are still a lot of questions. Which vaccines have received full approval? When will we see vaccines approved for children under ...
Mar 17, 2022
0
2
MUSC Hollings Cancer Center oncologists found that using a combination monoclonal antibody (tixagevimab-cilgavimab) against the SARS-CoV-2 spike protein in patients with blood cancers prevented moderate and severe COVID cases. ...
Dec 16, 2022
0
18
